NCT06865924View on ClinicalTrials.gov

Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis

NAActive, not recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
PSC
Interventions
OTHER

Use of assembloids as in vitro models to test new pharmacological approaches

Using extracellular vesicles containing the CRISPR/Cas9 genome editing system that by faithfully reproducing the in vivo part will allow a more faithful response than the use of conventional 2D model, organoids or animal model.

Trial Locations (1)

20122

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica, Milan

All Listed Sponsors
lead

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

OTHER

NCT06865924 - Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis | Biotech Hunter | Biotech Hunter